Trends in life-science fundraising
Submitted by Gary Li, PhD, R&D Leader, Scientific and Venture Advisor.
Originally published in Life Sciences Insights Magazine, September 2024
The life-science startup funding scene has experienced dramatic swings in the past four years. The current market has been in moderate recovery mode from its summer 2022 bottom. While some clinical stage startups with experienced management teams are able to raise mega rounds, many companies at various stages are struggling to survive and layoffs are stacking up.
As a biotech executive (Ignyta, BridgeBio and RayzeBio) and advisor for multiple venture capital (VC) firms, Gary Li, PhD, identifies the following trends as most noteworthy in current life-science fundraising.
Clinical stage companies are heavily favored by investors. While early-stage startups are still expected to elaborate on a clear path toward clinic, investors are concentrating capital on companies that have already de-risked that transition.
Multi-asset pipeline appears to be much more favorable than a single-asset approach. A balanced pipeline is viewed as a time-tested strategy for mitigating risk and increasing efficiency.
Differentiation is key. Despite significant advances in genetics, biology and discovery technologies in the past decades, good therapeutic targets are still hard to come by. Numerous programs are crowded into the limited number of validated targets, and investors are having a tough time picking the winners.
Management team with a strong track record matters a lot. The quality and experience of the founding team is a primary consideration in investor decision-making.
Besides traditional VC firms, corporate VCs are stepping up to support early-stage startups. Not only do they invest as a syndicate investor, but they are also increasingly taking on a lead role. For startups, finding potential synergy with corporate VC backers (big pharma) is a good strategy to initiate the discussion.
Additionally, for early stage startups whose platform or lead programs are not mature enough to attract private funding, government grants and not-for-profit foundation grants are good alternatives.
Get the latest thought leadership from California’s life sciences sector in the quarterly Life Sciences Insights magazine. Share your own news and insights with CLS Member Voice.
FAQ: Trends in life-science fundraising
The market has been in moderate recovery since its 2022 low. Investors are prioritizing clinical stage companies, multi-asset pipelines, differentiated programs, and experienced management teams over early-stage or single-asset ventures.
Investors focus on a clear clinical pathway, a differentiated therapeutic approach, and the quality and track record of the founding team. A multi-asset pipeline is increasingly viewed as a stronger risk profile than a single-asset bet.
Yes. Corporate VCs are increasingly taking lead roles in early-stage rounds, not just participating as syndicate investors. Identifying strategic synergies with corporate VC backers, including large pharma companies, can be an effective way to start the conversation.
Government grants and not-for-profit foundation grants are viable alternatives for early-stage startups whose platforms or lead programs are not yet mature enough to attract private investment.
Good therapeutic targets remain scarce despite decades of advances in genetics and biology. Many programs compete for the same validated targets, which makes it difficult for investors to distinguish winners and increases pressure on companies to demonstrate a meaningfully differentiated approach.